27-28 June 2018

Twitter logo for website footers 2


Day One
Wednesday 27th June, 2018

Day Two
Thursday 28th June, 2018

Breakfast & Registration

Chairman’s Opening Remarks

Lessons Learned from the Leaders

Kymriah: The Journey of the First Approved CAR-T from Bench to Ensuring Global Availability for Patients

  • Pascal Touchon Senior Vice President, Global Head Cell & Gene, Novartis Oncology


  • How do you take a product from bench through to bedside?
  • What are the key learnings from commercialization of the first CAR-T products?
  • What future challenges/obstacles do my CAR-TCR therapies face?
  • What is the biggest opportunity for the CAR-TCR space right now?
  • How do we translate success into more common cancers?

Commercialization Experience from Yescarta’s Debut


  • Regulatory requirements for approval in China
  • Streamlining manufacturing
  • Global tech transfer of cell therapy
  • In field experience of Yescarta commercialization
  • Customizing the product
  • Leveraging integrated technologies to orchestrate and support commercial activities
  • The paradigm shift in how we think about therapeutic supply chain
  • The commercial experience as a full service package
  • Leveraging partner relationships for close end-to-end co-ordination

Question Time: Leader Q&A


This is your opportunity to quiz the leaders in the space on developmental, clinical and commercial challenges. Hear from those in the trenches and identify your path to success for lessons learned by the leaders.

Morning Refreshments & Speed Networking

Targets beyond CD19

Quo Vadis CAR-T! The Next Frontiers in Cell Therapies


  • Broadening the therapeutic indications = targets beyond CD19
  • Translating the success of CAR-T = from hematological malignancies to solid tumors
  • Shortening development timelines = manufacturing without viruses
  • Expanding eligible patient populations = the promise of allogeneic off-the-shelf therapies
  • Multi-modal approaches = combining CAR therapies with immune modulators

Development of CAR-T Against Solid Tumors


  • The main challenges for CAR-T against solid tumor
  • Identification and validation of rational target for solid tumor
  • How to balance cancer-specificity and antigen heterogeneity in the development of CAR-T cells
  • Next-generation of CAR-T to overcome the hostile tumor microenvironment
  • How to development a rational combination

Chimeric Switch-receptor Targeting Innovative Inhibitory Receptor on CAR-T Construct


  • New CAR construct design
  • Non-clinical data
  • Preliminary clinical data


Lunch & Networking

Novel Gene Editing & Synthetic Biology to Improve Safety and Efficacy

Advancing Adoptive Immunotherapy with CRISPR/CAS9 Genome Editing Of T Lymphocytes

  • Yangbing Zhao Director of the T Cell Engineering Laboratory , Center for Cellular Immunotherapies, University of Pennsylvania


  • Rapid clinical trial development using high efficient multiplex CRISPR/CAS9 gene disruption of TRAC, TRBC and PD1 in a wild type TCR transferred T cells
  • Co-delivering a PD1-CD28 switch receptor further boosted in vivo anti-tumor activities of the CRISPR gene edited TCR transferred T cells
  • Improved tumor regression by co-delivering a PD1-CD28 switch receptor was due to enhanced TIL infiltrating, decreased susceptibility to tumor-induced hypofunction and resistance to tumor derived suppressions
  • Additional disruption of Tim-3 showed synergistic effect of controlling large, established solid tumors in mice
  • The application of a PD1-CD28 switch receptor to boost CRISPR/CAS9 gene edited,  TCR transduced T cell activity against solid tumors via a variety of mechanisms promotes clinical application of this potentially promising treatment modality

Develop an Efficient System to Build more Effective CAR-T Products for Solid Tumor by Synthetic Biology Technology


  • CAR T-cell therapy for solid tumors: novel strategies, immunological principles and drawbacks of current genetic engineering platform
  • State of art design efficient CAR molecules by synthetic biology technology
  • Design and optimize CAR molecules for solid tumors
  • The case study KD-025 CAR-T in live cancer
  • The case study KD-053 0r KD-082 CAR-T in pancreatic cancer
  • Combining synthetic biology and immunology: hacking CARs to expand their therapeutic capabilities

Suicide Switches to Improve Safety and Efficacy of CAR-TCR Therapies


  • Life after CARs: Long term outcomes and response rates
  • Types of suicide switches you can implement
  • Implementing an “off” switch to prevent toxicity and excessive T Cell action
  • Enhancing proliferation and activation of cells with the use of an “on” switch to super enhance cells
  • Gene engineering and the types of switches being used in CAR T cells


Allogeneic Versus Autologous

Panel: Can we Make Allogeneic CAR-T Therapies a Reality?


  • How can companies transition from autologous to allogeneic?
  • Is it possible to combine autologous/allogeneic manufacturing processes regardless of the therapy developed?
  • Can we create universal therapies?
  • What are the safety and efficacy consideration?
  • Are naturally off the shelf vehicles like NK cells a better approach?


Chairman’s Closing Remarks

Close of Day 1